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Influence of erythropoietin on paradoxical responses of growth hor-
mone to thyrotropin-releasing hormone in uremic patients. Several
alterations in growth hormone (GH) secretion have been reported in
patients with chronic renal failure. The aim of the present report has been
to assess the effect of acutely administered recombinant human erythro-
poietin (rHuEPO) infusion on GH responses to thyrotropin-releasing
hormone (TRH) in uremic patients. Twelve male patients (mean age 46.2
years, range 24 to 69) were studied. Seven of them were on continuous
ambulatory peritoneal dialysis (CAPD), two on chronic hemodialysis(HD) and two in pre-dialysis (PreD). None had been treated before with
rHuEPO. Each patient was tested with TR}I (400 sg i.v. in bolus), and
with TRH plus rHuEPO (40 U/kg in constant infusion for 30 mm) on
different days. TRH administration provoked a paradoxical response of
GH (peak > 5 sg/liter) in nine (5 CAPD, 2 HD, 2 PreD) out of 12
patients. In this group of patients with anomalous OH responses, rHuEPO
infusion produced an abolishment of the paradoxical responses (GH peak
<5 rg/liter) in eight patients and a marked decrease in a further one. On
the contrary, in patients with no paradoxical GH response, stimulation
with TRH plus rHuEPO did not induce any change in GH release
compared with that observed after TRH alone. rHuEPO had no effect on
TRH-induced thyrotropin release. These results suggest that the paradox-
ical OH response to TRH in patients with chronic renal failure is blocked
by rHuEPO administration. This rHuEPO action might be mediated by an
increased release of somatostatin or an inhibited GH-releasing hormone
secretion.
Correction of the anemia with recombinant human erythropoi-
etin (rHuEPO) in patients with end-stage renal disease has been
associated with improvement of several abnormalities in hypo-
thalamo-hypophyseal functions. Long-term therapy with this
agent in uremic patients undergoing maintenance hemodialysis
has been followed by improvement in sexual function in men and
women [1, 2], increase in plasma levels of testosterone in male
patients [3], normalization of prolactin levels [4], normalization of
the response of thyrotropin (TSH) to thyrotropin-releasing hor-
mone (TRH) [5], and restoration of follicle-stimulating hormone
responses to exogenous gonadotropin-releasing hormone [5]. A
better oxygen supply due to the improvement of anemia and a
direct trophic action of rHuEPO at hypothalamic or pituitary
levels have been speculated to be the causative factors of these
endocrine modifications.
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Growth hormone (GH) secretion appears to be altered by
rhEPO administration in patients with chronic renal failure. A
potentiation of GH responses to OH-releasing hormone (OHRH)
has been obtained in a group of hemodialyzed patients after acute
administration of an intravenous rHuEPO infusion [6], supporting
the hypothesis of a direct effect of rHuEPO on OH secretion.
However, conificting results have been reported on OH responses
to GHRH after chronic treatment with rHuEPO in uremic
patients. Thus, some investigators found that rHuEPO treatment
potentiated GH secretion after GHRH stimulation [7], while
more recently RamIrez et a! [8] have shown that correction of the
anemia with rHuEPO did not modify the exaggerated OH re-
sponses to OHRH in a group of five hemodialysis patients,
although it corrected the baseline elevation of GH plasma levels.
On the other hand, it is well known that a paradoxical increase in
OH levels after TRH administration is a frequent finding in
uremic patients [9]. This anomalous OH response was eliminated
by chronic rHuEPO therapy in a group of five hemodialyzed
anemic patients studied by RamIrez et al [5], although the
mechanism of this action could not be established. Therefore, the
aim of the present work has been to assess whether acutely
administered rHuEPO exerts any influence in paradoxical OH
increases obtained after TRH injection in a group of patients with
chronic renal failure, to give further insight into the pituitary
effects of rHuEPO.
Methods
Patients
Twelve male patients with chronic renal insufficiency were
studied. Six healthy volunteers with normal renal function (mean
plasma creatinine 92.8 4.4 p.mol/liter, blood hemoglobin con-
centration 8.73 0.26 mmol/liter) matched for age and body mass
index were studied as controls. The study was approved by the
Local Ethical Committee and informed consent was obtained
from all study participants before testing.
There were two patients on conservative management (predi-
alysis) with creatinine clearances of 13 and 15 ml/min, two
patients on hemodialysis (HD) and eight patients on continuous
ambulatory peritoneal dialysis (CAPD). Table 1 shows clinical
and analytical features of the nine patients found to be responders
to TRH. All patients were clinically stable, and did not receive
rHuEPO or any medication known to affect OH secretion. All
patients received aluminum hydroxide and water-soluble vitamins.
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Table 1. Clinical and analytical data of uremic patients with paradoxical response of OH to TRH
Patient
Age
years Diagnosis
Mode
of
therapy
Months of
dialysis
BMI
kg/rn2
Creatinine
p..'nol/liter
Hemoglobin
mrnol/liter
Albumin
g/liter
Baseline OH
pg/liter
GH peak OH peak after
after TRH EPO + TRH
pg/liter
1 31 CON Pre — 20.0 698 5.1 44 1 7 4
2 49 CON Pre — 273 522 7.6 46 2 10 7
3 44 Un HD 48 20.8 1105 5.7 43 5 21 4
4 33 IN HD 84 24.7 1096 5.6 44 3 10 4
5 31 PKD CAPD 7 27.2 972 7.8 44 1 12 3
6 24 NH CAPD 5 21.5 787 6.9 48 1 7 4
7 69 PKD CAPD 89 16.0 796 6i 31 2 9 3
8 42 DN CAPD 15 27.2 955 6.4 42 9 26 2
9 63 DN CAPD 46 20.0 645 65 32 1 7 4
Mean 42.89 42.00 22.7 841.8 6.41 41.56 2.78 12.11 3.89
SEM 5.09 13.23 1.34 67.7 0.30 1.99 0.89 2.26 0.45
Controls (N = 6)
Mean 37.17 24.9 92.8" 8.73" 46.5 1.00 1.2 3.0
SEM 5.33 1.04 4.4 0.26 0.89 0.10 0.2 1.76
Abbreviations are: OH, growth hormone; TRH, thyrotropin-releasing hormone; BMI, body mass index; CON, chronic glomerulonephritis; Un,
unknown; IN, interstitial nephropathy; PKD, polycystic kidney disease; HN, hypertensive nephrosclerosis; DN, diabetic nephropathy; Pre, pre-dialysis;
I-ID, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis.
ap < 0.005, "P < 0.001, controls vs. patients
Three patients (no. 8 and 9 in Table 1, and 1 non-responder) were
insulin-treated diabetics. They were in regular metabolic control,
as judged by their concentrations of hemoglobin Ale, which
ranged from 7.5 to 8.3%. Five patients (no. 3, 6 and 8, and 2
non-responders) were hypertensive and were treated with calcium
channel blockers or angiotensin converting enzyme inhibitors with
adequate control of blood pressure. All patients were on a stable
diet containing about 147 kJ/kg/day and about 1 to 1.4 g/kg high
biological value protein per day. Body mass index (BMI) ranged
between 16.0 and 30 kg/rn2 (mean 24.0 1.21) in patients and
between 20 and 27.3 kg/rn2 (mean 24.87 1.04) in controls
(differences not significant). Serum albumin concentration ranged
between 31 and 48 g/liter (mean 40.3 1.6) in patients and
between 44 and 50 g/liter (mean 46.5 0.89, P C 0.05) in controls.
We could not find any statistically significant difference in the
values of BMI and serum albumin between patients divided
according to their modality of therapy (conservative, HD, CAPD)
or the presence or absence of diabetes mellitus or hypertension.
Likewise, there were no significant differences in the values of
transferrin and prealbumin in the diverse groups of patients (HD
vs. CAPD, diabetics vs. non-diabetics; data not shown).
Study design
Endocrine tests were begun at 08:30, after an overnight fast,
with the subjects recumbent. In patients on HD the studies were
performed on the day preceding a dialysis session. An indwelling
catheter was placed in a forearm vein and kept patent with a slow
infusion of 0.9% NaCI. Thirty minutes later the first blood sample
was collected. Each subject received TRH (TRH Prem, Zyma-
Frumtost, Switzerland), 400 tg i.v. in bolus at time 0. Blood
samples were collected at —30, 0, 15, 30, 60, 90 and 120 minutes.
In another experiment, seven days apart, subjects were tested with
TRH plus rHuEPO (Erantin, Boehringer Mannheim, OmbH,
Germany), 40 lU/kg body weight, infused at a constant rate for 30
minutes, starting 15 minutes before TRH administration. The
tests with TRH alone and TRH plus rHuEPO were performed in
randomized order, In all blood samples plasma OH and TSH
concentrations were assessed, Blood hemoglobin concentration
and hematocrit values and serum concentrations of albumin,
creatinine, free thyroxine and triiodothyronine were also deter-
mined at time 0 in one of the experiments.
Hormone assay
Blood samples were centrifuged immediately and the plasma
stored at —20°C until assayed. Human plasma OH and TSH
concentration were determined by using an automated immu-
noenzymatie assay (Tosoh, AlA 1200). Maximal intra-assay and
interassay coefficients of variation of OH assay were 5.4% and
3.3%, respectively. The sensitivity of the OH assay was 0.1
pg/liter. For TSH assay, the sensitivity was 0.06 gU/mI and
maximal intra-assay and interassay coefficients of variation were
3.3% and 3.4%, respectively. Thyroxine and triiodothyronine were
measured by commercially available radioimmunoassay kits (Am-
ersham, Arlington Heights, Illinois USA). Blood hemoglobin
concentrations and hematocrit values were measured in a Coulter
Counter, and the serum chemistry determinations were made
using an automated multichannel analyzer (Technicon).
Statistical methods
Results are expressed as mean SEM. The areas under the
secretory curve (AUC) were calculated between 0 and 120
minutes by a trapezoidal method. For statistical evaluation of the
OH and TSH responses after TRH alone and after TRH plus
rhEPO administration, the obtained values were analyzed by
using the Wilcoxon's signed rank test. For comparisons between
patients and control subjects the Mann-Whitney test was em-
ployed. The differences were considered to be significant when P
<0.05.
Results
Growth hormone
A paradoxical response of OH in the TRH test was considered
to be present when the OH peak after TRH administration was
higher than 5 xg/liter. According to this criterion, 9 (75%) out of
the 12 studied patients showed this anomalous response (Table 1).
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Fig. 1. Plasma growth hormone responses to TRH (400 pg. i.v., airow)
(open circles) and to TRHplus rhEPO (40 U/kg body wt iv. infusion for 30
mm, rectangle) (closed circles) in the 9 uremic patients with paradoxical
growth hormone responses to TRH. Abscissa scale: time (mm). Ordinate
scale: plasma growth hormone concentrations (sg/liter). Each point
represents the mean SEM. < QØ5, < 0.01.
In this group of patients rHuEPO infusion produced an abolish-
ment of the paradoxical response (that is, peak < 5 .tg/liter) in
eight patients and a marked decrease in a further one (patient no.
2). Mean (±sEM) values of GH peak, which were reached at
different times in individual patients, in responsive patients (N =
9) were 12.11 2.26 pg/liter after TRH stimulation and 3.89
0.45 pg/liter after TRH plus rHuEPO infusion, being this differ-
ence statistically significant (P < 0.01).
Figure 1 represents the mean values of GH levels throughout the
time period of the tests performed in the group of nine patients with
paradoxical response. When TRH was injected during rHuEPO
infusion GH release was significantly less than after the administra-
tion of TRH alone, reaching these differences the limit of statis-
tical significance between 30 and 120 minutes. The area under the
curve of GH secretion in this group of patients was 16.08 4.44
hr/liter after TRH challenge and 4.43 0.71 .tg hr/liter (P <
0.01) after TRH plus rHuEPO infusion (Table 2).
On the contrary, in patients who showed no paradoxical re-
sponse to TRH, the administration of TRH during rHuEPO
infusion did not induced any significant change in GH release in
comparison with that observed after TRH alone. In these patients
the mean values of GH peak and AUC were 1.33 0.33 p.g/liter
and 2.08 0.08 pg hr/liter, respectively, after TRH stimulation
and 2.30 0.88 pg/liter and 2.63 0.58 pg hr/liter, respectively,
after TRH plus rHuEPO.
In healthy volunteers TRH did not produced any paradoxical
response of GH in any subject. When tested with TRH plus
rHuEPO one subject showed a OH peak of 10 pg/liter at 120
minutes, with the remaining OH levels being 1 pg/liter. In the
remaining five subjects GH concentrations were always at levels
equal or less than 2 xg/liter throughout the tests.
Patients
(N=9)
Controls
(N=6)
Baseline GH pg/liter
GH peak after TRH
2.78 0.89
12.11 2.26
1.0 0.10
1.2 020b
pg/liter
GH peak after EPO + TRH 3.89 0.45 3.0 1.76
pg/liter
GH AUC after TRH 16.08 4.44 2.08 0.08
pg hr/liter
GH AUC after EPO + TRH 4.43 0.71 2.52 0.45
pg• hr/liter
Baseline TSH U/ml 2.80 0.51 1.47 0.29
TSH peak after TRH 10.17 2.12 10.0 2.08
sU/ml
TSH peak after EPO + TRH 9.67 1.98 8.67 1.76
isU/ml
TSH AUC after TRH 17.68 3.39 14.64 2.85
pUhr/ml
TSH AUC after EPO + TRH 17.34 3.19 12.71 1.62
hr/mi
Free thyroxine 19.7 1.54 17.8 1.80
pmol/liter
Triiodothyronine 1.37 0.10 1.39 0.16
nmol/liter
Baseline GH concentration were not significantly different
between normal subjects and uremic patients with or without
paradoxical responses to TRH. There were no relationships
between the presence of paradoxical OH responses and the age of
the patients, the hemoglobin concentration, hematocrit value,
time of dialysis, BMI or the presence of diabetes or hypertension.
No particular features of patients with paradoxical response
compared with patients without such a response were identifiable.
Thyrotropin
All patients showed plasma concentrations of thyroxine and
triiodothyronine that were not different from those found in
normal subjects (Table 2). Baseline TSH concentration in healthy
volunteers were 1.47 0.29 U/ml. These levels reached a peak
of 10.0 2.08 U/ml 30 minutes after TRH stimulation. When
this stimulus was injected during rHuEPO infusion there were no
significant modification in the time (30 mm) or the magnitude
(8.67 1.76 kUIml) of the TSH peak (Table 2). The group of
nine uremic patients with paradoxical responses of GH showed
baseline TSH levels (2.80 0.51 xU/ml) slightly higher but not
significantly different than those found in normal subjects. The
TSH peak was elicited in these patients at 30 minutes of TRH
administration and reached a value of 10.17 2.12 .tU/ml when
TRH was administered alone and 9.67 1.98 jxU/ml when TRH
was injected in the rHuEPO infusion (P> 0.05). No significant
differences were observed between TSH responses to TRH (esti-
mated by peak and AUC) in the presence or in absence of
rHuEPO in uremic patients. Neither was there any difference
between TSH responses obtained in patients and controls or
between TSH responses in patients divided according to the
presence or absence of paradoxical GH response (data not
shown).
No subjective side effects were reported during the tests either
in control subjects or in patients with chronic renal failure.
Table 2. Baseline and stimulated hormonal concentrations in GH-
responder uremic patients and control subjects
L
0
E
0
I
12
10
8
6
4
2
0
I I
—30 0
— £ t
30 60 90 120
Data are mean SEM.
P < 0.05, b P < 0.005 controls vs. patients
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Discussion
Data reported here confirm that TRH can induce a OH release
in some patients affected by chronic renal insufficiency, in accor-
dance with previous reports [9—12]. Results of the present paper
also show that the paradoxical OH response to TRH in patients
with end-stage renal disease is significantly reduced by acute
rhEPO administration. This effect of rhEPO was independent of
the age of the patients, the degree of anemia, the mode of therapy,
the duration of dialysis or the presence of diabetes or hyperten-
sion. Therefore, a clear relationship between OH responsiveness
to TRH and the patient characteristics could not be established.
These results are in agreement with those obtained by RamIrez
and coworkers [5], who reported that chronic therapy with rhEPO
was accompanied by a disappearance of the paradoxical OH
reaction to TRH in hemodialyzed patients.
In normal humans, TRH does not modify OH release. How-
ever, the so-called 'paradoxical' increase in OH in response to
TRH has been documented in certain pathological situations. In
renal failure, TRH-induced OH release was first observed by
Oonzález-Barcena et al [9] as an unexpected finding in seven of
eight uremic patients given TRH to study TSH secretion. Several
authors have confirmed this uremia-associated hormonal de-
rangement [5, 11], and have shown that these anomalous OH
reactions are more pronounced in patients with more severe
degrees of renal funcional impairment [12] and are not sup-
pressed by triiodothyronine administration [10], thus suggesting a
separate mechanism for the release of OH and TSH. Paradoxical
OH responses to TRH are also well known findings in patients
with acromegaly [13], hypothyroidism [14], anorexia nervosa [15],
diabetes mellitus [16] and liver cirrhosis [17]. Therefore, it seem
that TRH is a non-specific OH stimulator in several pathological
conditions. The mechanism of this abnormal response remains
unclear. In rats it has been shown that TRH can elicit OH
secretion from normal or tumoral somatotropic cells, thus sug-
gesting a direct pituitary stimulatory action [18—20]. It has been
also proposed that a decrease in hypothalamic release of soma-
tostatin [21] or an increase in GHRH secretion [22] at the median
eminence might be involved in OH release after TRH stimulation.
How can rhEPO interfere with these hormonal regulatory
systems to block the paradoxical responses is a question that
remains unsolved with the present results. RamIrez et al [5]
suggested that correction of the anemia, accompanied by a
relative nutritional improvement, might normalize OH secretion
and, hence, eliminate the paradoxical response. However, this
explanation cannot account for the findings encountered in acute
experiments such as those herewith reported. Rather, a direct
effect of rhEPO at hypothalamic or pituitary level seems likely.
Interestingly, the concomitant administration of rhEPO and
OHRH potentiated the response of OH to OHRH in hemodia-
lyzed patients [6]. These data, together with results reported here
support the hypothesis that rhEPO by itself, without correction of
the anemia, can modulate the response of somatotrophs through
a mechanism different from increased oxygen supply.
We have previously hypothesized that rhEPO might act at the
hypothalamic level by decreasing OHRH secretion [23, 24]. In
fact, erythropoietin has recently been considered as one of the
several growth factors [25] and functional similarities between
erythropoietin and insulin-like growth factor type I (JOE I)
molecules have been reported [26]. Therefore, it can be specu-
lated that rhEPO might act as a JOE I-like substance at the
hypothalamic level and, accordingly, reduce OH responses to
TRH through an increase of somatostatin release or a reduction
of the release of OHRH as it has been demonstrated for JOE I
[27]. This mechanism of action might also account for the
reduction in OH responses to some hypothalamic stimuli reported
by our group in uremic patients undergoing CAPD [23] and by
others in hemodialyzed patients treated with rhEPO [28].
Separate pathways in the neuroregulation of OH and TSH
secretion in uremic patients have been proposed [10]. In fact, we
could not find any effect of acutely administered rhEPO on TSH
response to TRH. This is in agreement with results reported by
other authors [29, 30], who found no change in TSH responses to
TRH after partial correction of the anemia by means of several
weeks of rhEPO therapy in hemodialyzed patients. Nonetheless,
RamIrez et al [5] encountered that TSH responses to TRH were
markedly potentiated after rhEPO therapy. It is likely that the
disparate populations of patients we have examined could explain
some discrepancies between our results and previously published
studies.
In summary, results here reported show that anomalous OH
reactions to TRH are reduced by acutely administered rhEPO in
uremic patients. We are aware of the limited scope of our results,
but we think that these data, together with those previously
reported by others [5—8, 28], suggest that rhEPO therapy may
improve some of the uremia-associated derangements in OH
secretion. The mechanisms by which rhEPO affects somatotropic
cell function in patients with chronic renal failure remain to be
elucidated. It is no doubt that a better oxigenation of the
hypothalamo-hypophyseal areas may give rise to an improvement
in OH secretion; however, the data in our study also suggest that
a direct modulatory action of rhEPO may not be ruled out. In vitro
studies about rhEPO effects on hypothalamic and pituitary func-
tions have been suggested [31], but are lacking at present time.
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